Treatment Horizons for Triple-negative Breast Cancer

Full Article

W Yeo

Hong Kong J Radiol 2015;18:111-8

DOI: 10.12809/hkjr1515321

Triple-negative breast cancer is a distinct clinical subtype characterised by tumours that do not express oestrogen receptor, progesterone receptor, or HER-2 oncogene. Patients with triple-negative breast cancer have been reported to have a poor outcome. The mainstay of systemic treatment is chemotherapy. It has been noted that triple-negative breast cancer may be further sub-classified and one of the subclasses is the BRCA-associated tumour. In this article, systemic treatment for triple-negative breast cancer in the advanced metastatic, neoadjuvant, and adjuvant setting will be discussed. In particular, recent data in relation to the role of platinum compounds and poly (ADP-ribose) polymerase inhibitors will be reviewed.